ICSs: improving patient and market access at a local level
Integrated Care Systems (ICSs) – 42 partnerships of health and care organisations who will plan and deliver more joined-up services for their locality in England […]
Deep Dive: Market Access
Time is motor neurons – the importance of newborn screening in SMA
Spinal muscular atrophy (SMA) is a devastating, genetic neuromuscular disease caused by a lack of a functional SMN1 gene that results in the progressive and […]
Is it time to rethink electronic prescribing in the US?
It is a fact of life that most – if not all – patients will require some form of prescription medication during their lifetime. Generally, […]
Combination pricing: access to the future of oncology treatment relies on collaboration
Combination therapies are fast becoming the cornerstone of cancer treatment: not just in the UK, but across the world. With strong evidence to support how […]
Closing the digital expectation gap in pharma
Jan Deman is Takeda’s head of digital customer experience for Europe and Canada. But he’d prefer not to refer to what he does as “innovation”. […]
How do we make patient centricity a reality?
For years, the subject of fostering direct connections with patients has been highlighted by notable figures across the healthcare and life sciences industries as a […]
Leveraging KOL insights to succeed in a data-driven world
For years, key opinion leaders (KOLs) have held a position of authority and respect amongst those working across the life science industry, be it a […]
Rethinking value: why diverse viewpoints matter
Value is a tricky concept to capture accurately. Given the diverse and complex world that we live in, different people will often hold contrasting views […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
Turning words into actions with patient engagement
Boehringer Ingelheim’s Carinne Brouillon tells us how the company co-created its recent Global Patient Partnership Summit with patients and how the meeting brought representatives together […]
How the patient voice is becoming vital for drug approval
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores […]
“A long way to go” for digital health reimbursement
A recent analysis delves into the challenges companies face in getting digital health technologies reimbursed and presents recommendations for how these products can find a […]
Time for a NICE change
The National Institute for Health and Care Excellence (NICE) is world-renowned for their work assessing the clinical and cost-effectiveness of new treatments. In recognition of […]
Rethinking access barriers to innovation
Market access issues don’t stop once a product has passed HTA – and this is especially true for disruptive therapies like ATMPs. Experts from Executive […]
AI meets RWE: The future of drug assessment?
Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for pharma […]
Listening to ultra-rare disease communities
When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. As a global commercial biopharmaceutical company pioneering therapies for ultra-rare […]
How to improve payer engagement with tailored value communication
Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate strong value propositions in increasingly crowded therapeutic […]
From representation to empowerment: Putting patients at the centre of medicine reimbursement
Experts from Vynamic discuss their vision for a future where patients are at the heart of medicine reimbursement in Europe – and provide actionable steps […]
How will NICE fare in a post-Brexit world?
NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts […]
Research predicts the post-COVID landscape for HCP engagement
IQVIA’s Liz Murray takes us through the company’s latest research into HCPs’ attitudes to pharma engagement, and asks how pharma sales forces can adapt for […]
A year on: pandemic driven trends in HCP engagement
IQVIA’s John Procter explores why the industry should be paying attention to the changing HCP customer experience in the wake of COVID-19. This article appears […]
